pharmaphorum
JUNE 7, 2021
Researchers in the US have developed a wearable fabric that can sense, store and analyse data that could be used to measure physiological functions or detect illness. The team from Massachusetts Institute of Technology (MIT) claim this is the first example of a fabric which can record data in a digital rather than in an analogue format, allowing it to be programmed like any other digital device.
Outsourcing Pharma
JUNE 7, 2021
The virtual clinical development firmâs analysis of patient profiles reflects obesity is the most significant indicator for severity in those under 40.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
JUNE 8, 2021
Anyone with a smart device has been feeling the grueling effects of social isolation and screen fatigue since the start of the COVID-19 outbreak. Recently, we have witnessed a flood of new “audio-social apps” and audio features on social media platforms, aiming to finds new ways to connect, curb loneliness and cut excessive screen exposure. What are some of these audio-focused platforms and where can pharma play a role?
Pharma Times
JUNE 10, 2021
Three Gold Standards awarded for partnership work in patient advocacy and communications
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JUNE 9, 2021
“Rarely does the answer come from the boardroom” – what can user experience teach us about building accessible digital health? No one should be left behind as the world embraces digital healthcare say leading user experience voices. The experts discussed the benefits and merits of co-creation during a session on bridging the digital divide, held during the recent Patient Experience Digital Summit.
Outsourcing Pharma
JUNE 8, 2021
In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinsonâs cohort, to aid future research.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Times
JUNE 11, 2021
New guidance enables earlier access to certain treatments, including biologics
pharmaphorum
JUNE 11, 2021
A digital therapeutic aimed at people with chronic lower back pain based on virtual reality (VR) has shown encouraging results in a clinical trial, helping patients manage the fear of movement that can reduce their activity and impede recovery. The therapy uses a VR headset to guide people with chronic pain through a series of cognitive behavioural therapy (CBT) exercises that are designed to help them overcome the fear of movement – also known as kinesiophobia.
Outsourcing Pharma
JUNE 7, 2021
The US Food and Drug Administration (FDA) has approved Biogenâs Aduhelm (aducanumab) for the treatment of Alzheimerâs: making it the first new treatment approved for the disease since 2003.
BuzzRx
JUNE 10, 2021
A headache is a very common problem. Most people have experienced one at some point in their lives. In fact, according to the International Headache Society, National Headache Foundation, and World Health Organization, 75% of people have had a headache within the past year. But not all headaches are the same. A headache can cause throbbing or dull pain, constant pain or pain that comes and goes, and pain all over the head or only on one side.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
JUNE 9, 2021
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
pharmaphorum
JUNE 11, 2021
The development of vaccines for COVID-19 has been a masterclass in effective collaboration and applied digitisation in healthcare. However the increased complexity and involvement of different parties, exposes manufacturers to heightened threat levels. Abel Archundia discusses how COVID-19 has highlighted the importance of securing clinical trials against cyber threats.
Outsourcing Pharma
JUNE 7, 2021
The pharmacy company's Wegovy (semaglutide) is the first therapy designated for chronic weight management that the agency has granted approval since 2014.
Pharma Marketing Network
JUNE 10, 2021
Robin Kamen is an experienced innovator in digital strategy with a deep background in leadership positions for healthcare and consumer products companies. She has worked with many omnichannel brands to use digital marketing technologies to improve B2C and B2B customer engagement funnels and drive sales and retention. She is also skilled in developing the change management often needed to secure buy-in for and to successfully operate digital strategies.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
JUNE 9, 2021
Under Operation Pangea, officers were also able to shut down or block 113,000 illegally operating websites
pharmaphorum
JUNE 8, 2021
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. Home to over 60% of the world’s population, Asia Pacific (APAC) is not a region the biopharma industry can afford to ignore. Dr Jay Mei, founder and CEO of Antengene, notes that the region has rich innovation resources but also urgent medical needs, leading to both opportunities and uncertainties for the industry.
Outsourcing Pharma
JUNE 8, 2021
A leader from the manufacturing technology provider talks about how companies can work to streamline oral solid dose manufacturing to remain competitive.
Lifewell Rx Pharmacy
JUNE 9, 2021
According to a study published in the National Library of Medicine, medication non-adherence may lead to “worsening condition, increased comorbid diseases, increased health care costs, and death.” To prevent this, patients must work with a pharmacy to store prescriptions correctly. For example, packaging plays a vital role in promoting medication adherence.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Times
JUNE 7, 2021
Conditional marketing authorisation granted for the treatment of recurrent or advanced endometrial cancer
pharmaphorum
JUNE 7, 2021
Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences’ Kite subsidiary is now looming in the rear view mirror – armed with new data for its already-filed rival Tecartus. Results of the phase 1/2 ZUMA-3 trial of Tecartus (brexucabtagene autoleucel) reported at the ongoing ASCO conference revealed a 71% complete response rate with the CAR-T in heavily pre-treated adult patients with B-cell precursor ALL.
Outsourcing Pharma
JUNE 10, 2021
A leader from the virtual research solutions specialist discusses how a greater pushed toward home-based research can lead to a range of benefits.
Pharma Marketing Network
JUNE 9, 2021
Join PMN on July 15th for our premier event on Customer Experience, where we will discuss best practices for moving beyond buzzwords to elevate experience and drive true patient and provider engagement based on empathy and data insights. Hear from leading Experience and Omnichannel experts from Merck, BMS, Novartis, AstraZeneca, UCB, AbbVie, and more on winning strategies to transform data into actionable strategy, elevate CX beyond campaign optimization and activate the “Engagement Matrix” in y
Pharma Times
JUNE 9, 2021
The NIHR-supported RECOVERY trial found that the anti-inflammatory drug does not improve survival for hospitalised patients with COVID-19
pharmaphorum
JUNE 9, 2021
The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry as a whole? Analysts at RBC Capital Markets say that the decision points to an unprecedented shift in position for the FDA when it comes to regulating drugs for neurological and psychiatric disorders – and while the potential for Aduhelm may still be speculative , other drug developers could see big
Outsourcing Pharma
JUNE 10, 2021
The two organizations have formed a public-private partnership aimed at improving nonclinical research through better practices and standardization.
Druggist
JUNE 8, 2021
Venlafaxine & weight gain? The focus of this post is to explore evidence be one of the most common side effects of venlafaxine. Additionally, I will talk about other aspects of venlafaxine, including licensed use, and common side effects. What is Venlafaxine? Venlafaxine is an antidepressant drug used to treat major depression, general and social anxiety disorders and panic conditions (BNF, 2021).
Pharma Marketing Network
JUNE 7, 2021
Tom Croce is vice president for global patient advocacy at bluebird bio, inc., the clinical-stage biotech company that develops gene therapies for severe genetic and rare diseases. He and his team are responsible for identification and integration of patient perspectives across the entire development and commercial continuum, while ensuring meaningful company representation to patient, caregiver and advocate partners around the world.
pharmaphorum
JUNE 11, 2021
The fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest. . The latest to depart the FDA’s Peripheral and Central Nervous System Drugs panel is Aaron Kesselheim of Harvard Medical School, joining fellow committee members Joel Perlmutter and David Knopman who quit earlier this week.
Outsourcing Pharma
JUNE 8, 2021
The US agencyâs latest actions and advice against the virus include information on test recalls, , approval and reauthorization of treatments, and more.
Pharma Mirror
JUNE 6, 2021
Terrassa (Barcelona): Telstar will be exhibiting the latest developments in aseptic technology for pharmaceutical production and integrated turnkey engineering & construction services for process facilities at Achema Pulse 2021. The company will be present at the digital flagship event of the global process industries during the whole of June and will be live during 15-16th June.
Pharma Times
JUNE 7, 2021
JCVI will advise on whether this younger age group will be vaccinated routinely
pharmaphorum
JUNE 8, 2021
The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” Biogen meanwhile has bee
Outsourcing Pharma
JUNE 8, 2021
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced or metastatic breast cancer (MBC).
Expert insights. Personalized for you.
145 
Let's personalize your content